These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21466257)

  • 61. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes.
    Díez-Aguilar M; Morosini MI; López-Cerero L; Pascual Á; Calvo J; Martínez-Martínez L; Marco F; Vila J; Ortega A; Oteo J; Cantón R
    J Antimicrob Chemother; 2015 Aug; 70(8):2306-10. PubMed ID: 25900161
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
    Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antimicrobial resistance of
    Majewski M; Józefiak A; Kimsa-Furdzik M; Dziubdziela L; Hudak-Nowak M; Wilczyński J; Anusz K
    Ann Agric Environ Med; 2021 Jun; 28(2):271-276. PubMed ID: 34184510
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli.
    María DA; María-Isabel M; María-Carmen C; Álvaro P; Jorge C; Luis MM; Francesc M; Jordi V; Adriana O; Jesús O; Rafael C
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):334-6. PubMed ID: 26830054
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Surrogate testing of oral third-generation cephalosporin susceptibility to common uropathogens.
    Watson JR; Burch C; Leber AL
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115299. PubMed ID: 33460959
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Global forecast of antimicrobial resistance in invasive isolates of Escherichia coli and Klebsiella pneumoniae.
    Alvarez-Uria G; Gandra S; Mandal S; Laxminarayan R
    Int J Infect Dis; 2018 Mar; 68():50-53. PubMed ID: 29410253
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Relationships between resistance to cefoxitin, ciprofloxacin and amoxicillin-clavulanic acid in Escherichia coli clinical isolates].
    Fernández-Cuenca F; Amblar G; Pascual A; Martínez-Martínez L
    Enferm Infecc Microbiol Clin; 2005 Oct; 23(8):510-1. PubMed ID: 16185572
    [No Abstract]   [Full Text] [Related]  

  • 68. Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.
    Baker KR; Jana B; Hansen AM; Nielsen HM; Franzyk H; Guardabassi L
    Front Cell Infect Microbiol; 2019; 9():236. PubMed ID: 31334131
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differences in the in vitro susceptibility of planktonic and biofilm-associated Escherichia coli strains to antimicrobial agents.
    Naves P; Del Prado G; Ponte C; Soriano F
    J Chemother; 2010 Oct; 22(5):312-7. PubMed ID: 21123153
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antimicrobial resistance among pilgrims: a retrospective study from two hospitals in Makkah, Saudi Arabia.
    Haseeb A; Faidah HS; Bakhsh AR; Malki WH; Elrggal ME; Saleem F; Rahman SU; Khan TM; Hassali MA
    Int J Infect Dis; 2016 Jun; 47():92-4. PubMed ID: 27312582
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Amoxicillin-clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings.
    Duytschaever G; Huys G; Boulanger L; De Boeck K; Vandamme P
    J Cyst Fibros; 2013 Dec; 12(6):780-3. PubMed ID: 23867070
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Saunders KA; Miller LA; Poupard JA
    Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):261-7. PubMed ID: 12709842
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain.
    Oteo J; Campos J; Lázaro E; Cuevas O; García-Cobos S; Pérez-Vázquez M; de Abajo FJ;
    Emerg Infect Dis; 2008 Aug; 14(8):1259-62. PubMed ID: 18680650
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Automated time-lapse microscopy a novel method for screening of antibiotic combination effects against multidrug-resistant Gram-negative bacteria.
    Ungphakorn W; Lagerbäck P; Nielsen EI; Tängdén T
    Clin Microbiol Infect; 2018 Jul; 24(7):778.e7-778.e14. PubMed ID: 29108951
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unacylated tridecaptin A₁ acts as an effective sensitiser of Gram-negative bacteria to other antibiotics.
    Cochrane SA; Vederas JC
    Int J Antimicrob Agents; 2014 Dec; 44(6):493-9. PubMed ID: 25315408
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Urinary microflora in children from different pediatric departments].
    Kaltenis P; Murauskaite G; Bernatoniene G
    Medicina (Kaunas); 2003; 39 Suppl 1():94-7. PubMed ID: 12761428
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The garden in our gut.
    Kmietowicz Z
    BMJ; 2015 Sep; 351():h5161. PubMed ID: 26424008
    [No Abstract]   [Full Text] [Related]  

  • 78. [Multiple antibiotic resistance of associative microflora during urogenital pathology].
    Akaeva FS; Omarova SM; Adieva AA; Medzhidov MM
    Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):85-7. PubMed ID: 19186554
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nanoscale structure-activity relationships, mode of action, and biocompatibility of gold nanoparticle antibiotics.
    Bresee J; Bond CM; Worthington RJ; Smith CA; Gifford JC; Simpson CA; Carter CJ; Wang G; Hartman J; Osbaugh NA; Shoemaker RK; Melander C; Feldheim DL
    J Am Chem Soc; 2014 Apr; 136(14):5295-300. PubMed ID: 24624950
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections.
    Fransen F; Melchers MJB; Lagarde CMC; Meletiadis J; Mouton JW
    J Antimicrob Chemother; 2017 Dec; 72(12):3366-3373. PubMed ID: 28961900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.